Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan

International Journal of Cardiology

Volumn 97, Issue 3, 2004, Pages 383-388

  Mattioli, A V ^a   Zennaro, M ^a   Bonatti, S ^a   Bonetti, L ^a   Mattioli, G ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Angiotensin II receptor blocker; Diastolic function; Left atrium; Left ventricular hypertrophy; Left ventricular mass; Telmisartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; TELMISARTAN;

ADULT; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART SINGLE VENTRICLE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PULMONARY VEIN; REMISSION; TREATMENT OUTCOME;

BENZIMIDAZOLES; BENZOATES; DIASTOLE; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROSPECTIVE STUDIES; SYSTOLE;

EID: 9244251540     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.10.018     Document Type: Article

References (34)

1. Aeschbacher B.C., Hutter D., Fuhrer J., Weidmann P., Delacretaz E., Allemann Y. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am. J. Hypertens. 14:2001;106-113
2. Modena M.G., Mattioli A.V., Parato V.M., Mattioli G. Effectiveness of the antihypertensive action of lisinopril on left ventricular mass and diastolic filling. Eur. Heart J. 13:1992;1540-1544
3. Lip G.Y. Regression of left ventricular hypertrophy and improved prognosis: some HOPE now... or hype? Circulation. 104:2001;1582-1584
4. Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 104:2001;1615-1621
5. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am. J. Hypertens. 5:1992;95-110
6. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am. J. Hypertens. 14:2001;174-182
7. Dahlöf B., Zanchetti A., Diez J., Nicholls M.G., Yu C.M., Barrios V., et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J. Hypertens. 20:2002;1855-1864
8. Thürmann P.A., Kenedi P., Schmidt A., Harder S., Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 98:1998;2037-2042
9. Malmqvist K., Kahan T., Edner M., Held C., Hagg A., Lind L., et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J. Hypertens. 19:2001;1167-1176
10. Isobe N., Taniguchi K., Oshima S., Ono Z., Adachi H., Toyama T., et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ. J. 66:2002;993-999
11. Dahlöf B., et al. for the LIFE study group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2003;995-1003
12. Petrovic J., Popovic Z., Petrovic D., Djuric D. Telmisartan influence on endothelial dysfunction in hypertensive patients. J. Renin-Angiotensin- Aldosterone Syst. 1:2000;74. [abstract PA.17]
13. Ivanova O.V., Fomicheva O.A., Sergakova L.M., Chernova N.A., Rogoza A.N., Karpov Y.A. Angiotensin II receptor blocker telmisartan: effect on 24-hour blood pressure profile and left ventricular hypertrophy in patients with ypertension. Kardiologiia. 42:2002;42-49
14. Galzerano D., Tammaro P., Cerciello A., Breglio R., Mallardo M., Lama D., et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J. Hum. Hypertens. 18:2004;53-59
15. Alizade I.G., Alieva-Karaeva N.T. Long-term effects of Pritor on left ventricular mass and diastolic function in hypertensive patients. J. Hypertens. 20(Suppl. 4):2002;S340. [abstract R005]
16. Wienen W., Richard S., Champeroux P., Audeval-Gerard C. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J. Renin-Angiotensin- Aldosterone Syst. 2:2001;31-36
17. Böhm M., Lippoldt A., Wienen W., Ganten D., Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol. Cell. Biochem. 163/164:1996;217-221
18. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch. Intern. Med. 153:1993;154-183
19. Mattioli A.V., Sansoni S., Lucchi G.R., Mattioli G. Serial evaluation of left atrial dimension after cardioversion for atrial fibrillation and relation to atrial function. Am. J. Cardiol. 85:2000;832-836
20. Sahn D.J., DeMaria A., Kisslo J.W.A. The Committee on M-mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 58:1978;1072-1083
21. Levy D., Savage D.D., Garrison R.J., Anderson K.M., Kannel W.B., Castelli W.P. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am. J. Cardiol. 59:1987;956-960
22. Nishimura R.A., Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: doppler echocardiography is the clinician's Rosetta Stone. J. Am. Coll. Cardiol. 30:1997;8-18
23. Rossvoll O., Hatle L.K. Pulmonary venous flow velocities recorded by transthoracic Doppler ultrasound: relation to left ventricular diastolic pressures. J. Am. Coll. Cardiol. 21:1993;1687-1696
24. de Simone G., Verdecchia P., Pede S., Gorini M., Maggioni A.P. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension. 40:2002;470-476
25. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 102:2000;470-479
26. Tedesco M.A., Ratti G., Aquino D., Limongelli G., di Salvo G., Mennella S., et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J. Hum. Hypertens. 12:1998;505-510
27. Okin P.M., Devereux R.B., Jern S., Julius S., Kjeldsen S.E., Dahlöf B. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am. J. Hypertens. 14:2001;775-782
28. Rusconi C., Sabatini T., Faggiano P., Ghizzoni G., Oneglia C., Simoncelli U., et al. Prevalence of isolated left ventricular diastolic dysfunction in hypertension as assessed by combined transmitral and pulmonary vein flow Doppler study. Am. J. Cardiol. 87:2001;357-360. [abstract A10]
29. Matsuzaki M., Tamitani M., Toma Y., Ogawa H., Katayama K., Matsuda Y., et al. Mechanism of augmented left atrial pump function in myocardial infarction and essential hypertension evaluated by left atrial pressure-dimension relation. Am. J. Cardiol. 67:1991;1121-1126
30. Mattioli A.V., Bonetti L., Vandelli R., Fontanesi L., Mattioli G. Atrial function and size after conversion of atrial fibrillation in hypertensive patients. Am. J. Hypertens. 14:2001;160A. [Suppl., abstract]
31. Braunwald E., Frahm C.J. Studies on Starling's law on the heart: IV. Observations on the hemodynamic functions of the left atrium in man. Circulation. 24:1961;633-642
32. Stangier J., Su C.-A.P.F., van Heiningen P.N.M., Meinicke T., van Lier J.J., de Bruin H., et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J. Cardiovasc. Pharmacol. 38:2001;672-685
33. Neutel J., Smith D.H. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J. Clin. Hypertens. 5:2003;58-63
34. Mancia G., Parati G. Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality. Blood Press. 3:2002;26-32. [Suppl.]